Allahwerdy Fady, Pan Steven, Feehan Michael, Jones Aubrey E, Munger Mark A, Witt Daniel M
Department of Pharmacotherapy, College of Pharmacy, University of Utah. Salt Lake City, UT (United States).
Kantar LLC, San Francisco, CA (United States).
Pharm Pract (Granada). 2019 Jul-Sep;17(3):1539. doi: 10.18549/PharmPract.2019.3.1539. Epub 2019 Aug 22.
The objective of this study is to describe the most common self-reported antithrombotic therapy utilization patterns in a national cohort of patients with recent venous thromboembolism (VTE).
Extant data from a national online survey administered to 907 patients 18 years of age or older with VTE in the last two years were analyzed. Patients' self-reported antithrombotic usage patterns used during three phases of treatment for the most recent VTE episode were summarized using descriptive statistics.
The following overall antithrombotic usage patterns were identified: warfarin (38.7%), direct oral anticoagulants (DOACs) (26.1%), switching between warfarin and DOACs (13.3%), aspirin only (8.7%), switching between different DOACs (4.5%), injectable anticoagulants only (3.9%), and no treatment (4.7%). Extended antithrombotic therapy beyond 90 days was reported by 65.7% of patients. Aspirin coadministration with anticoagulant therapy occurred for 33.7%.
In this national sample of recent VTE sufferers warfarin therapy remains the most used anticoagulant followed closely by DOAC therapy. Switching between warfarin and DOACs and between different DOACs was common which could indicate adverse events or affordability issues. Aspirin coadministration with anticoagulant therapy was present in 1 of 3 patients and is a potential medication safety intervention for anticoagulation providers.
本研究的目的是描述全国近期静脉血栓栓塞症(VTE)患者队列中最常见的自我报告的抗血栓治疗使用模式。
对一项针对过去两年内907名18岁及以上VTE患者进行的全国在线调查的现有数据进行分析。使用描述性统计方法总结了患者在最近一次VTE发作的三个治疗阶段中自我报告的抗血栓药物使用模式。
确定了以下总体抗血栓药物使用模式:华法林(38.7%)、直接口服抗凝剂(DOACs)(26.1%)、在华法林和DOACs之间切换(13.3%)、仅使用阿司匹林(8.7%)、在不同DOACs之间切换(4.5%)、仅使用注射用抗凝剂(3.9%)以及未进行治疗(4.7%)。65.7%的患者报告了超过90天的延长抗血栓治疗。33.7%的患者将阿司匹林与抗凝治疗联合使用。
在这个全国性的近期VTE患者样本中,华法林治疗仍然是使用最广泛的抗凝剂,紧随其后的是DOAC治疗。在华法林和DOACs之间以及不同DOACs之间的切换很常见,这可能表明存在不良事件或可负担性问题。三分之一的患者将阿司匹林与抗凝治疗联合使用,这对抗凝治疗提供者来说是一种潜在的药物安全干预措施。